Pharmacogenomics and Vaccine Development

Although pharmacogenetics and pharmacogenomics entered mainstream clinical medicine on the drug side, diffusion into the biologics side of clinical medicine has been slow-most notably regarding human vaccines. The consequence is an inadequate science base upon which to leverage new ways of understanding, designing, and evaluating vaccines-particularly for hypervariable viruses and complex pathogens.

Automated summary

Pharmacogenetics and pharmacogenomics are well integrated into the drug side of clinical medicine, but diffusion into the biologics side, particularly in the field of human vaccines, has been slow. This has resulted in a lack of scientific foundation for understanding, designing, and evaluating vaccines, especially for hypervariable viruses and complex pathogens.